Medicenna Therapeutics (TSE:MDNA) Stock Price Down 3.8% – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) shares were down 3.8% on Monday . The company traded as low as C$1.17 and last traded at C$1.27. Approximately 47,723 shares were traded during trading, a decline of 27% from the average daily volume of 65,261 shares. The stock had previously closed at C$1.32.

Medicenna Therapeutics Stock Performance

The company has a market cap of C$97.07 million, a PE ratio of -3.34 and a beta of 1.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 2.51. The firm’s 50 day moving average is C$1.59 and its 200-day moving average is C$1.93.

Insider Activity at Medicenna Therapeutics

In other news, Senior Officer David Hyman bought 20,000 shares of Medicenna Therapeutics stock in a transaction on Thursday, January 9th. The shares were bought at an average cost of C$1.45 per share, with a total value of C$29,000.00. Insiders own 22.57% of the company’s stock.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.